BX-U001

N/A

Report date: 2025/12/30 20:00:13

Base Information

Drug NameBX-U001
Drug Alias NamehUC-MSC suspension - BaylxHuman umbilical cord tissue-derived mesenchymal stem cell therapy - BaylxBX-U001BC-U001
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOrion Corp
China Registration ClassN/A

Develop Information

Active CompaniesBaylx Inc
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult

Other Information

ATC CodeN/A
Related LinksN/A